Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Up 588,312.5% in April

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a significant increase in short interest in April. As of April 30th, there was short interest totaling 94,146 shares, an increase of 588,312.5% from the April 15th total of 16 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 591,063 shares, the short-interest ratio is presently 0.2 days.

Oncotelic Therapeutics Stock Up 5.9%

Shares of OTCMKTS:OTLC traded up $0.00 during midday trading on Monday, reaching $0.04. The company had a trading volume of 1,408,932 shares, compared to its average volume of 284,886. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.07 and a quick ratio of 0.07. The stock’s fifty day moving average price is $0.04 and its 200-day moving average price is $0.07. The stock has a market capitalization of $17.52 million, a P/E ratio of 0.07 and a beta of -0.54. Oncotelic Therapeutics has a one year low of $0.02 and a one year high of $0.11.

Oncotelic Therapeutics (OTCMKTS:OTLC) last announced its earnings results on Wednesday, April 15th. The company reported $0.59 earnings per share (EPS) for the quarter.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.